Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib + ASTX727 vs ASTX727 in Higher-Risk IDH2-Mutated MDS
NCT06577441Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of enasidenib in myelodysplastic syndrome (MDS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Complete response rate. Started Jun 2025; status: recruiting.
02
Drugs
enasidenib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06577441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577441.